
ERA 25: Data Underscore Iptacopan’s Effect on Proteinuria and Complement Activation in IgAN
New data from a phase 2 trial and its ongoing open-label extension (OLE) highlight the reversibility and reinducibility of the effects of iptacopan (Fabhalta) on proteinuria and complement activation in patients with IgA nephropathy (IgAN). Presented at …